Russell Investments Group
OVID icon

Russell Investments Group’s Ovid Therapeutics OVID Stock Holding History

Russell Investments Group’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-447
Closed -$417 – 3858
2024
Q4 		$417 Sell
447
-1,317
-75% -$1.47K ﹤0.01% 3628
2024
Q3 		$2.08K Buy
1,764
+166
+10% +$173 ﹤0.01% 3367
2024
Q2 		$1.23K Buy
+1,598
New +$4.45K ﹤0.01% 3413
2023
Q4 		– Sell
-57
Closed -$219 – 3282
2023
Q3 		$219 Buy
+57
New +$205 ﹤0.01% 3487
2023
Q2 		– Sell
-267,459
Closed -$690K – 3511
2023
Q1 		$690K Sell
267,459
-1,256
-0.5% -$2.98K ﹤0.01% 2142
2022
Q4 		$500K Hold
268,715
– – ﹤0.01% 2287
2022
Q3 		$492K Buy
268,715
+847
+0.3% +$1.77K ﹤0.01% 2251
2022
Q2 		$574K Sell
267,868
-8,105
-3% -$19.6K ﹤0.01% 2217
2022
Q1 		$865K Sell
275,973
-30,583
-10% -$96.2K ﹤0.01% 2023
2021
Q4 		$983K Buy
+306,556
New +$1.05M ﹤0.01% 2155
2021
Q2 		– Sell
-104,283
Closed -$419K – 3274
2021
Q1 		$419K Buy
+104,283
New +$346K ﹤0.01% 2594
2019
Q1 		– Sell
-500
Closed -$1K – 2988
2018
Q4 		$1K Buy
+500
New +$2.28K ﹤0.01% 2902

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Russell Investments Group's OVID Position: Q1 2025 in Review

Russell Investments Group sold out of Ovid Therapeutics (OVID) in Q1 2025, closing a stake of 447 shares — an estimated $417 sold.

Russell Investments Group first reported a position in OVID in Q4 2018 and held it in 12 quarters. The position peaked at $983K in Q4 2021. 82 funds tracked by Wall St. Rank hold OVID as of Q1 2025.

  • Russell Investments Group reported no remaining Ovid Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Russell Investments Group sold 447 Ovid Therapeutics shares in Q1 2025, an estimated $417.
  • Russell Investments Group first reported a position in Ovid Therapeutics in Q4 2018 and held it in 12 quarters.
  • Russell Investments Group's Ovid Therapeutics position peaked at $983K in Q4 2021.
  • 82 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2025.

Based on Russell Investments Group's 13F filing for Q1 2025, filed 13 May 2025.